Stoke Therapeutics (STOK) Operating Expenses (2018 - 2026)

Stoke Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $59.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 26.03% year-over-year to $59.6 million; the TTM figure through Mar 2026 stood at -$46.3 million (down 120.52% YoY), while the FY2025 annual figure was -$13.7 million, down 109.94% from the prior year.
• Operating Expenses was $59.6 million for Q1 2026 at Stoke Therapeutics, up from -$155.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $147.1 million in Q4 2024 to a low of -$155.9 million in Q4 2025.
• Historically, Operating Expenses has averaged $24.6 million across 5 years, with a median of $30.4 million in 2022.
• Biggest YoY gain for Operating Expenses was 2468.82% in 2025; the steepest drop was 205.93% in 2025.
• A 5-year view of Operating Expenses shows it stood at $30.4 million in 2022, then gained by 6.39% to $32.4 million in 2023, then soared by 354.33% to $147.1 million in 2024, then slumped by 205.93% to -$155.9 million in 2025, then soared by 138.27% to $59.6 million in 2026.
• The last three Operating Expenses figures came in at $59.6 million (Q1 2026), -$155.9 million (Q4 2025), and $53.7 million (Q3 2025), per Business Quant data.